首页> 外文期刊>Journal of breath research >Efficacy of a new mouthrinse formulation on the reduction of oral malodour in vivo. A randomized, double-blind, placebo-controlled, 3 week clinical study
【24h】

Efficacy of a new mouthrinse formulation on the reduction of oral malodour in vivo. A randomized, double-blind, placebo-controlled, 3 week clinical study

机译:新的漱口混霉素制剂对体内口服恶臭减少的疗效。 随机,双盲,安慰剂控制,3周临床研究

获取原文
获取原文并翻译 | 示例
       

摘要

The present study was conducted to assess the efficacy of a new mouthrinse formulation in reducing oral malodour compared to that of commercially available products containing chlorhexidine (CHX) and a negative control. 174 healthy volunteers, each with an organoleptic score of at least 2 and an H_2S level as part of the volatile sulfur compounds (VSC) higher than 50 ppb, were divided into four groups. Participants were stratified according to their organoleptic ratings (OR). Group I: mouthrinse I (250 ppm F~- from amine fluoride/stannous fluoride (ASF), 0.2% zinc lactate, oral malodour counteractives); group II: mouthrinse II (0.05% CHX, 0.05% cetylpyridinium chloride, 0.14% zinc lactate); group III: mouthrinse III (0.12% CHX); group IV: tap water. All groups were instructed to perform standardized oral hygiene measures and to apply the respective test rinse twice daily after tooth brushing. Malodour was assessed by organoleptic measurement and by VSC levels at baseline, day 1, day 7, day 14 and day 21 into the study. To evaluate discolouration of the teeth, the colour was assessed at baseline and final visit. The ASF mouthrinse showed superior efficacy as compared to the negative control. A significant reduction in OR and VSC readings was achieved after single application as well as after 7 and 21 days of continuous use. Between test groups I-III no statistically significant differences were found at any time point. There was also a trend towards fewer side effects caused by the ASF product compared to the products containing CHX. The newly developed mouthrinse product significantly reduces oral malodour in patients with increased values both in OR and in VSC.
机译:进行本研究以评估新的漱口虫制剂在减少口服恶臭中的疗效,而含有氯己定(CHX)和阴性对照的商业上可用的产品。 174个健康的志愿者,每个具有至少2个和H_2S水平的感官志愿者,作为挥发性硫化合物(VSC)的一部分高于50ppb,分为四组。参与者根据他们的感官评级(或)分层。 I族:漱口剂I(250 ppm f〜 - 来自胺氟/芳烃(ASF),0.2%锌乳酸,口服杀菌抵消);第II组:漱口剂II(0.05%CHX,0.05%十六烷吡啶氯化锡,0.14%锌乳酸盐);第三组:漱口乳III(0.12%CHX);第四组:自来水。所有群体都被指示进行标准化口腔卫生措施,并在刷牙后每天两次应用相应的测试冲洗。通过感官测量和基线,第1天,第7天,第14天和第21天的VSC水平评估了恶作剧进行评估。为了评估牙齿的变色,在基线和最终访问中评估颜色。与阴性对照相比,ASF漱口混霉素显示出优异的功效。单一申请后达到或vsc读数的显着减少以及在连续使用的7和21天后实现。在测试组之间,I-III在任何时间点都没有发现统计学上显着的差异。与含有CHX的产品相比,ASF产品造成的副作用较少。新开发的漱口体产品显着减少了VSC中患者患者的口服恶臭。

著录项

  • 来源
    《Journal of breath research》 |2010年第1期|共10页
  • 作者单位

    ProDERM Institute Applied Dermatological Research GmbH Schenefeld Germany;

    ProDERM Institute Applied Dermatological Research GmbH Schenefeld Germany;

    ProDERM Institute Applied Dermatological Research GmbH Schenefeld Germany;

    ProDERM Institute Applied Dermatological Research GmbH Schenefeld Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内科学;
  • 关键词

  • 入库时间 2022-08-20 08:51:09

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号